This guideline is adapted for inter-professional primary care providers working in various settings in VIHA and any other clinical practice setting in which a user may see the guidelines as applicable.
Opioid withdrawal occurs when an opioid is discontinued abruptly. Withdrawal symptoms last for a few days and are generally the opposite of symptoms exhibited when the opioid was started. (1) Opioid naïve patient refers to an individual who has either never had an opioid or who has not received repeated opioid dosing for a 2 to 3 week period. (6) Opioid tolerance is a state of adaptation in which exposure to a drug induces changes that result in a diminution of one or more of the drug's effects over time. (7, 8) It is a known pharmacologic effect of opioids. (8) Tolerance to the analgesic effects of opioids is relatively uncommon. (7) Physiologic dependence is a state of adaptation that is manifested by a drug class specific withdrawal syndrome that can be produced by abrupt cessation, rapid dose reduction, decreasing blood level of the drug and / or administration of an antagonist. (8) Addiction is a primary, chronic, neurobiological disease, with genetic, psychosocial and environmental factors influencing its development and manifestations. It is characterized by behaviours that include one or more of the following: impaired control over drug use, compulsive use, continued use despite harm and craving. (9) Non-Opioid is a term used to describe drugs that are structurally and functionally unrelated to opioids but whose primary indication is for the treatment of pain. (10) Examples are: acetaminophen, acetylsalicylic acid (ASA) or non-steroidal anti-inflammatory drugs (NSAIDs). (1) Adjuvant analgesics (sometimes known as coanalgesics) are medications whose primary indication lies elsewhere, but which have been found to be beneficial in the management of some types of pain. Commonly used adjuvants are: corticosteroids, anti-psychotics, antidepressants, anti-convulsants and bisphosphonates. Other adjuvant therapies used include radiation, intrathecal and epidural analgesia, nerve blocks and surgery.(1)
Standard of Care
• Opioid Principles Opioid Principles
• Opioids can and should be used for both cancer and non-cancer pain where other measures, including non-opioid analgesics, are insufficient to control debilitating pain. (11) • Opioids are the drugs of choice for moderate to severe pain associated with advanced illness. (12) (13) (14) (15) (16) • When the pain is only mild to moderate but expected to worsen, starting a stronger opioid may avoid another drug switch.(1) • When introducing opioids for the older adult, the dose should be 1/2 to 1/3 of the regular adult dose -"start low, go slow" and carefully monitor for side effects (38) • Long-acting or sustained-release analgesic preparations should be used for continuous stable pain (16) after a titration period with short acting to determine opioid requirements.
• Medical use of opioids for pain associated with advanced illness rarely, if ever, leads to drug abuse or opioid addiction.(13) • There is no ceiling or maximal recommended dose for strong opioids. (15) Large doses may be needed to manage pain associated with advanced illness. (8, 17) • Use oral route whenever possible. (18) There is no perfect route of administration; the plan must be individualized to the patient and the setting.
(1) • When writing opioid orders, remember to order medications to cover the 3 "B's" -Bowels, "Barfing" and Breakthrough. (2, 16, 17, 19) • Consider opioid rotation if there are adverse effects from, or tolerance to, the current opioid.(2) • It is not recommended to administer two different opioids (e.g., regular morphine with codeine or hydromorphone for breakthrough) at the same time (20) unless the duration of relief desired is not able to be achieved with one. For example, using IR opioids with fentanyl patches or sufentanil for incident pain when using long acting (SR) opioids.
• Meperidine has little use in the management of chronic pain and is rarely used in the palliative setting. (15, 21) • Opioid use does not shorten survival. (16) • Documentation of the use of opioids contributes to appropriate dosing and pain control. (22) Recommendation 2 Screen for Sensitivity or Allergy to Specific Opioid
• Most "allergies" to morphine are not true allergies but rather adverse effects. (13) • The only absolute contraindication to the use of an opioid is a history of a true hypersensitivity reaction. (16) • Opioids cause histamine release with subsequent itch and rash, which is sometimes mistaken for an allergic reaction. (13) More potent opioids are less likely to release histamine. (35) • Patients allergic to one opioid are not likely to be allergic to another opioid in a different structural class. (35) o Phenylpiperidine class -meperidine, fentanyl, sufentanil, remifentanil • Education of and appropriate management of possible adverse effects of opioids help to avoid situations where patients and / or families assume that they are "allergic" or can never take a drug again. Whether or not the underlying cause(s) can be relieved or treated, all patients will benefit from management of this symptom using education or medication.
Recommendation 5 World Health Organization Principles

World Health Organization's (WHO) Pain Relief Ladder for Cancer Pain(18)
If pain occurs, there should be prompt oral administration of drugs in the following order: non-opioids (ASA and acetaminophen); then, as necessary, mild opioids (codeine); then strong opioids such as morphine or hydromorphone, until the patient is free of pain. Adjuvant drugs should be used for specific pain etiologies. To maintain freedom from pain, drugs should be given "by the clock", that is every 3 to 6 hours (depending on the drug), rather than "on demand". This three-step approach of administering the right drug at the right dose at the right time is inexpensive and 80 to 90% effective.(18)
WHO's Pain Relief Ladder
Cancer Pain
Step One: for very mild pain a non-opioid analgesic (such as acetaminophen or ASA) maybe adequate. (7, 18) Step Two: if the pain is moderately severe a weak opioid plus or minus appropriate adjuvant agent(s) may provide adequate analgesia. (7, 18) Step Three: for severe pain, or when it is expected that pain will become severe, it is best to start with a low dose of a strong opioid and titrate up the dose according to effect. (7, 18) A weak opioid is one that has a ceiling effect, which may be due to a low affinity for opioid receptor sites. (1) The W.H.O Principles can be summed up as follows:(7)
• By mouth oral route is the route of administration of choice.
• By the clock analgesic medications for moderate to severe pain should be given on a fixed dose schedule, not on an as needed basis.
• By the ladder analgesics given per the W.H.O three step ladder.
• For the individual the dosage must be titrated against the particular patient's pain.
• Use of adjuvants to enhance analgesic effects, to control adverse effects of opioids and to manage symptoms that are contributing to the patient's pain (anxiety, depression or insomnia).
• Attention to detail determine what the patient knows, believes and fears about the pain and things that can relieve it. Give precise instructions for taking the medication.
Recommendation 6 Opioid Formulations
Commonly used first line oral opioids include codeine, morphine, hydromorphone, and oxycodone. They share the following characteristics:
• Half-life of immediate release preparations is 2 to 4 hours with duration of analgesic effect between 4 to 5 hours when given at effective doses. • Fentanyl is 80 to 100 times more potent than morphine. (1, 14) • A recent study reported less constipation and somnolence in patients using transdermal fentanyl compared to those using SR morphine. • Nausea/vomiting -usually mild and rarely persistent, (1, 9, 23) tolerance develops rapidly. (7, 12) Antiemetics can generally be discontinued in a few days when tolerance develops. (8, 17) See VIHA End of Life Symptom Guidelines on Nausea and Vomiting for guidance in choosing an antiemetic.
• Sedation -often transient, especially when opioid initiated or increasing doses. (14, 17) Will generally be relieved in 2 to 4 days. (1, 7-9, 12, 16, 23) Persistent opioid induced sedation is usually best treated by reducing the dosage and increasing the frequency of administration -this decreases peak concentrations while maintaining the same total dose. (8, 17) The use of psychostimulants may be beneficial. (8, 12, 14, 16, 17) • Delirium/restlessness -may be seen both upon initiation of opioids (frequently in the elderly) (1, 12) and may occur during ongoing opioid therapy when metabolite accumulation occurs. (1, 12, 25) For treatment of true delirium see VIHA End of Life Symptom Guidelines on Delirium / Restlessness. • Urinary retention occurs secondary to increased tone of the bladder sphincter and inattention to the stimulus for bladder emptying. This will generally decrease within one week.(9) Rarely will a patient need to be catheterized. (1, 9, 14) Urinary retention occurs more frequently in men with hyperalgesia (heightened sensitivity to the existing pain), allodynia (a normally non-noxious stimuli resulting in a painful sensation), agitation/delirium with hallucinations and possibly seizures. (1, 9, 12) It is due to the accumulation of toxic metabolites and impaired renal function, dehydration and electrolyte imbalances contribute to this condition. (1, 9, 21) OIN occurs more frequently with high dose parenteral administration of morphine (12) and has been observed in cases using high dose hydromorphone.
(1) OIN occurs more common in the frail elderly.(9) Grand mal seizure associated with high-dose parenteral opioid infusions have been reported and may be due to preservatives in the solution. Preservative free solutions should be used when administering high-dose infusions. (16) Opioid rotation should be considered. (1, 21) • Respiratory depression occurs rarely in patients receiving opioids regularly as tolerance to the respiratory depressant effect develops rapidly. (1, 7-9, 14, 16, 17) Opioids should not be withheld for fear of respiratory depression in this group. (17) The risk of respiratory depression is greater in patients with respiratory impairment (pneumonia, those with CO2 retention or chronic obstructive pulmonary disease), and when opioids are used in opioid-naïve patients, or are too rapidly titrated. (1, 9, 17) Recommendation 9 Opioid Titration
• When starting an opioid, use immediate release (IR) until dose is stabilized. Alternatively, when pain is mild or moderate, some clinicians may choose to start with an oral controlled-release (CR) formulation, with an IR form available for breakthrough pain. (13) • In opioid naïve patients start with 2.5 to 5 mg of morphine po or 0.5 to 1 mg of hydromorphone po q4h with breakthrough medication ordered at 1.25 to 2.5 mg of morphine po or 0.25 to 0.5 mg hydromorphone po q1h prn.
• Analgesic effectiveness can be reassessed after 24 hours as it takes five half lives to reach a steady state (5 x 4 hrs = 20 hrs).
• Total all the regular and breakthrough opioid used in the last 24 hours to get the total daily dose (TDD).
• Divide this amount by the number of doses for the next 24 hours (normally 6=q4h) and give this dose regularly q4h with 10% of the TDD given q1h p.r.n. as a breakthrough/rescue dose (BTD) for breakthrough/rescue pain. (2) • Dose adjustments should not be made more frequently than every 24 hours.(2) Also assess for end of dose pain, and the presence of incident pain, which may require further titration.
• Use IR opioid formulations for breakthrough doses (BTD) (13) and remember to increase the breakthrough dose proportionately when the regular dose is increased. (2) • When full pain relief is achieved, yet adverse effects have developed, employ a dose reduction to try and maintain adequate pain control with diminished adverse effects. (2) • Doubling the nightime dose will avoid wakening the patient in the early morning for a scheduled q4h dose, however, night loading doses should be considered only for patients with good pain control. (2,22) The use of sustained release opioids appears to be a better dosing strategy, as shown in a study with SR morphine.(26) • When good pain control is achieved with a stable dose with an immediate release formulation, consider use of a long acting product to improve compliance.(2) • When the patient is on sustained release opioids or fentanyl patches it is usual to titrate the dose every 48 and 72 hours respectively.(2) If fentanyl is used, total the amount of breakthrough opioid analgesic given in the last 24 hours and convert that amount to an additional equivalent size fentanyl patch. If titration is done frequently switch to a short acting preparation.
• If pain is rapidly escalating or pain is requiring frequent titration use short acting opioids q4h until pain is controlled and opioid needs are stabilized. Consider development of tolerance (which may require opioid rotation) or reassessment for a new or progressive medical problem.
• When patients are elderly or frail, titrate over a number of days rather than rapidly over 1 to 2 days.(2, 9) • For severe pain the rate of titration may need to be more aggressive. (14) Recommendation • Never prescribe sustained release oral formulations more frequently than q8h.
(1) • Never prescribe sustained release formulations on an as needed basis.
• SR tablet forms must be swallowed whole. Capsule forms may be opened up and the contents sprinkled onto food or put down a feeding tube but should not be crushed or chewed. (1, 15) • When using long-acting preparations, always give a short-acting opioid (solution or tablets) using the 10% TDD equivalency q1h p.r.n. for breakthrough pain (e.g., if the patient is on morphine sustained release 60 mg q12h PO give a breakthrough dose of morphine 10 to 15 mg PO q1h p.r.n.). (1, 7, 8, 12, 13, 17) Preferably use the same drug. (1, 14) • Fentanyl transdermal patches require changing q72h but some patients may require changing q48h. (1, 21) The full clinical effects of the fentanyl patch will occur between 24 and 48 hours after application; however, this varies greatly between patients.
Recommendation 11 Opioid Rotation
• Opioid rotation can be performed using the following methods: (1) o Direct substitution -is used with weaker opioids or in severe opioid-induced neurotoxicity. The offending opioid is stopped and the new one started.
o Gradual substitution -is used when switching between more potent opioids especially when there are already adverse effects or if the patient has anxiety about the new drug. Over the course of a few days the original analgesic is replaced by the new one.
•
Conversions between opioids:
o Due to in-complete cross-tolerance between opioids use 66-80% of the calculated equivalent dose. (2, 14) The dose should only be reduced if the pain was controlled on the previous medication dosage or if there was opioid-induced neuroexcitation pain.(1, 7, 8)
•
The most common reasons opioids are switched are inadequate pain control or an unacceptable level of adverse effects from a specific opioid which limits dose escalation. (1, 13, 14, 23) The need to switch occurs in 10 to 30% of patients on oral morphine. (2) Recommendation 12 Opioid Withdrawal
• Rationale for discontinuing an opioid would include patient achieving appropriate pain control by another method, such as radiation therapy, nerve block or epidural. (1, 7, 8, 14) • If the patient has been on opioids for only a short time, abrupt discontinuation should not incur withdrawal symptoms.(1) • If a patient has been on opioids for greater than one week it is suggested to taper the dose by 20 to 30% every 2 to 3 days until discontinued to prevent a withdrawal syndrome. (8) • An alternative method is; for the first 2 days, give half of the previous daily dosage. Then reduce the daily dosage by approximately 25% every 2 days, until a daily dosage of 30 mg of morphine has been reached. After 2 more days on 30 mg per day of morphine, discontinue use. (7) • Early symptoms include anxiety and restlessness, sweating, rapid short respirations, slight rhinorrhea and lacrimation and dilated reactive pupils.
• Late symptoms include marked rhinorrhea and lacrimation, tachypnea, tremor, yawning, pilo-erection, nausea and vomiting, diarrhea, abdominal pain, fever, leucocytosis and diffuse muscle spasms.
• Prolonged symptoms include irritability, fatigue, bradycardia and decreased body temperature.
• Withdrawal syndrome can also be precipitated by the use of opioid antagonists like naloxone. In the rare instance where this drug needs to be used, it should be mixed with 10 mL of saline and administered slowly in 1 mL increments to antagonize the respiratory depressant effects without precipitating an acute episode of withdrawal syndrome. (11, 13) Recommendation 13 Treatment: Non-pharmacological Support and encourage appropriate non-pharmacological strategies such as:
• Physical therapies -hot/cold, tens, ultrasound, hydrotherapy, yoga, positioning, immobilization, exercise, stretching, massage, OT, physio, compression stockings, special beds, skin care (36, 39) • Cognitive therapies -pain log/diary, biofeedback, hypnosis, relaxation, meditation, guided imagery, music therapy (36, 39) • Alternative therapies -aroma therapy, Reiki, therapeutic touch, acupuncture (36. 39) • Other therapies -spiritual support, psychological support, leisure activities (36, 39) These non-pharmacological strategies may provide additional comfort to patients but do not usually replace the need for pharmacological treatment in end of life care.
Recommendation 14
Treatment: Pharmacological
There are three simple goals for pain management;
• A good night's sleep, • Pain control during the day while at rest and • Pain control when they are active and ambulatory. (1) Where there is no previous history of opioid intake, the starting dose is calculated by assessing the severity of the pain, patient's age, weight, sex and general physical condition. • If currently on a weak opioid, discontinue it, start morphine PO q4h at the appropriate equianalgesic dose (taking into consideration the partial crosstolerance between opioids) with 10% TDD q1h p.r.n. for breakthrough pain.
MILD PAIN (Initial
(1) If more than three breakthrough doses are required over 24 hours, increase the morphine dose (as per above). Initial worst pain intensity between 7 and 10 should be considered a pain emergency and requires rapid titration using oral, subcutaneous or intravenous routes. (2, 31) 'When pain is high, go high and come down quickly'.(1) Use morphine, hydromorphone, or oxycodone.
SEVERE PAIN (Initial
Acute severe pain initially requires parenteral control with a switch to oral or rectal medication once the pain is relieved. If pain is sudden, acute and severe (i.e., fracture, hemorrhage), then both quick response and high doses are necessary. Once relief is obtained, dose can be reduced. The regimen assumes that usual breakthrough dosing has been ineffective.
• • If an I.V. bolus is warranted, give 10 to 20 % of the daily IV morphine equivalent. Reassess at 15 minutes. (31) The effectiveness of the analgesic should be reassessed after 15 minutes. If the pain intensity is unchanged the dose of the opioid should be doubled. If the rating has decreased by less than 50 %, the same dose should be repeated. Once the pain intensity has decreased by more than 50 % then calculate the total dose of opioid given over 4 hours and consider this dose the "effective"one to be given. (31) "Many painful conditions can be readily managed by generalist physicians, nurses and allied staff. Reality is such, however, that some pain problems are complex and require added expertise." (16) 
NSAIDS (Non-Steroidal Anti-inflammatory drugs)
• May be useful in mild to moderate nociceptive pain alone or in combination with opioids.
• It is believed that NSAIDs produce analgesia through a reduction in activation and sensitization of nociceptors caused by inflammatory mediators such as prostaglandins. (36) • Should not be used in patients with moderate pre-existing renal impairment -if used in patients with mild renal impairment, monitor creatinine in 5-7 days and stop if significantly elevated from baseline. The renal impairment is reversible upon discontinuation of the NSAID. (36) • Monitor blood pressure because in some patients NSAIDs can have quite a dramatic effect on blood pressure within a few days (39) • Do not use if on anticoagulants • Use with caution in elderly or patients with a history of gastric or duodenal bleed as the GI bleed risk is higher • Use with extreme caution in patients on corticosteroids as risk of ulceration and GI bleed risk is higher.
• Consider use of gastroprotective agent eg. proton pump inhibitor (pantoprazole)
• No evidence to suggest that one NSAID is more effective than another; however, if one NSAID is ineffective, it is reasonable to try another. Other adjuvants/co-analgesics:
• nerve blocks, epidurals, radiation ( • Non-invasive alternative to oral medications.
• Poor absorption of oral opioids.
• Pain that is stable;(1) pain controlled for at least 48 hours.
• To provide around the clock opioid treatment (1, 2) and improve patient compliance.(3,4) • To potentially lower opioid adverse side effects of constipation, (5, 6) nausea, (5) and histamine release. 
D. Properties
• 
E. Converting To Fentanyl Transdermal Patch
• Calculate the total daily dose of current opioid.
• Convert this into oral equivalent for morphine, hydromorphone or oxycodone.
• Use Fentanyl Transdermal Equianalgesic Conversion Chart to determine the equivalent dose of transdermal fentanyl.
• Always provide a breakthrough dose selecting the appropriate dose from the Approximate Breakthrough Doses Recommended for Fentanyl Transdermal Patchchart. Provision of breakthrough doses is important, as the conversion chart is conservative, (19) and approximate. Individualize patient treatment, for in clinical trials, 50% of patients required a dose increase after the initial patch strength application. (3) If breakthrough doses are given S.C. give one-half the oral dosage.
F. Initiation Of Fentanyl Transdermal Patch
• Apply patch to a non-hairy skin area on chest, back, flank or upper arm.(1,2) Note or record placement location to ensure removal in 72 hours time, prior to next dose replacement.
• During the first twelve hours after the patch has been started, utilize appropriate regular dosing during the transition, AS WELL AS p.r.n. dosing; refer to Conversion Guidelines Between Fentanyl Transdermal Patch and Oral and Subcutaneous Opioids Over First 12 Hours chart.
• Consider applying the first patch at bedtime, as lower pain requirements may occur at night, (20, 21, 22) permitting peak levels to occur during the day.
G. Dose Titration With Fentanyl Transdermal Patch
• Wait a minimum of three days between dose changes. (15) • Total amount of breakthrough doses in prior 24 hours to guide incremental dose increase.(19) • Consider a 30 to 50% baseline dose increase,(23) while using the available patch strengths. Thus after a patient was successfully initiated on a 12 mcg per hour patch, consider the following progressive steps: 12 » 25 » 37 » 50 » 75 » 100 » 150 » 200 mcg per hour etc.
• When less than a full patch dose is desired, a successfully used method is to apply an occlusive dressing (such as TEGADERM) onto the skin to block the appropriate surface area portion of the patch exposed to the skin., e.g. half the patch on the dressing and half on the skin.(24) • Rarely do patients require patches to be replaced more frequently than every three days. Early wearing off of the patch's effectiveness (end of dose failure) can indicate under-dosing and the need for the patch dose strength to be increased.
• Provide and appropriately adjust for a new p.r.n. breakthrough dose.(4,9)
H. Discontinuation Of Fentanyl Transdermal Patch
• Upon removal of the patch, the depot of medication within the subcutaneous skin tissue and drug elimination will diminish by 50% within seventeen hours of removal. 
I. Disposal of Fentanyl Transdermal Patch
• Used fentanyl patches may contain enough residual drug to cause serious problems for children, opioid-naïve patients and pets.
(1) Ensure they are disposed of properly: fold used patches in half then place in needle disposal container, or place in tamperproof container and return to a community pharmacy, to prevent misuse. (13) 
Appendix B METHADONE Principles
A. Characteristics
Of all the medications used in Palliative Medicine, methadone should command the greatest respect. Only physicians experienced in methadone use should initiate methadone treatment.(1-6) Its use is highly individualized, and demands finesse, skill and knowledge for use in carefully supervised settings.
Methadone is a potent analgesic utilizing OP3 (mu)(7) and OP1 (delta) (7) Side Effects:
The side effects of nausea, (12, 16) constipation, (3, 4, 6, 12, 16, 25) and confusion (6, 16) are often less than for other opioids. Additional side effects include sedation, dizziness, pruritus, sweating, vomiting, risk of urinary retention, dry mouth, and insomnia. (2, 3, 12, 14, 22) Several reports have been published of prolonged QTc (corrected QT interval), torsades de pointes (TdP) (a type of paroxysmal ventricular tachycardia) and syncope in patients taking high doses of methadone, greater than 200 mg per 24 hours. (6, 22, (26) (27) (28) Prolonged QT interval is associated with TdP, ventricular fibrillation and sudden cardiac death. (1, 9, 22, (29) (30) (31) Palliative care patients are at risk in the presence of heart disease, (22, 29) abnormal liver function, low potassium and calcium, and while using selected drugs. (7, 29, 32, 33) Refer to Table 2 for a list of drugs associated with prolonged QT interval and TdP.
Suppositories can be pharmaceutically compounded for rectal route use. (3, 5, 14, 23) Commercially, methadone is available in oral formulations of tablets of 1 mg, 5 mg. 10 mg, 25 mg and standard strengths of liquid 1 mg per mL and 10 mg per mL. Its bitter taste can be made more palatable by adding to liquids such as fruit juice (55) or chocolate milk. (5) Applesauce or a candy taken after a dose may alleviate the bitterness. (14) Methadone has been used intravenously (7, 8) subcutaneously, (35, 36) and intramuscularly, (14) although obtaining this form of the drug requires importation via Health Canada's Special Access Program http://www.hc-sc.gc.ca/dhp-mps/acces/drugs-drogues/index-eng.php
B. Properties
• OP3 (Mu)(2,7,37) agonist, OP1 (delta) (7, 37) and OP2 (kappa)(7,37) agonist and NMDA receptor (2, 4) antagonist.
• Serotonin and norephinephrine uptake inhibitor. (2, 25) • High bioavailablity 80% orally, (1) (2) (3) (4) 8, 12, 16, 23) 
C. Indications
• Opioid neurotoxicity. (4, 11, 14, 16, 17) • Opioid tolerance. (2, 11, 14, 16) • Uncontrolled neuropathic pain. (1, 4, 17, 21) • True morphine allergy.
• Treatment of cancer pain in patients on chronic methadone maintenance therapy. ( • Risk of respiratory depression, greatest at the start of therapy. (3, 13, 25) • Rotation best done as an inpatient, particularly when rapid opioid rotation desired. (3, 4, 15, 23, 42) Successful titration in the community has been done with daily health care contact (phone call) and frequent and regular assessment by the family until titration is complete. (23) Time to steady state is 48 to 240 hours,(6) and requires ongoing monitoring for up to 10 days after dose change to follow for drowsiness, risk of respiratory depression.
• Several drug interactions.(4,18) (see Table 1 ) • No randomized controlled trials to support its role in cancer (15, 34) and noncancer (44) pain management.
• No comparative studies regarding the effectiveness of the different methadone switching methods. (1, 4, 5, 9, 11, 34) • No comparative studies to provide an optimum titration strategy. (34, 45, 46) • Choice of breakthrough (rescue) drug not established in literature and clinical practice. (14) • Requires safeguards for use by patient only, to avoid accidental ingestion, as a 10 mg dose can be fatal for a child, or 40 mg for a non-tolerant adult. (14) Store in a childproof container within a locked box. (14, 15) E. Contraindications 
G. Dosages
Various methods are used to initiate methadone in patients. Suggested methods follow:
Opioid Naïve Patients: (Twycross)(48)
"start low go slow"
• Start with 5 mg q4h p.r.n.
• On day 4 summate doses and calculate q8h.
• 10% Total Daily Dose (TDD) for rescue.
• Alternate Regimen: (palliativedrugs.com newsletter Feb 2001).(49)
• Start methadone 5 mg q12h and 5 mg q3h p.r.n.
• If pain control inadequate increase to 10 mg q12h after 1 to 2 days; preference is not to change regular dose for 1 week.
• Can titrate up by 1/3 to 1/2 once a week.
• With higher regular doses increase the rescue dose to 1/8.
Dosing Guide For Opioid Tolerant Patients
Daily oral Morphine equivalents (1) Conversion ratio Morphine to Methadone(1) 
<100
Monitoring
• Monitor for sedation, lethargy, confusion and respiratory depression q6h for 3 to 6 days after initiation or dose change, then daily until at least day 10. Respiratory depression risk reported greatest from day 4 to day 6.(52) Pulse may slow and blood pressure lower in overdoses. (5) • Individualized patient dosing and evaluation is the best way to ensure the safe use of methadone.(5,23)
H. Drug Interactions:
For drug interactions known to occur with methadone, see below. Consult current sources for further and recent drug listings. The potential each of these drugs has to predispose to QT prolongation and torsades de pointes varies, but the extent is specific to the drug. Concomitant drug use in susceptible patients should be evaluated alongside other medical risk factors. Consult current sources for further and recent drug listings.
• Tramadol 75 mg with 650 mg acetaminophen is equivalent to 400 mg ibuprofen for postoperative pain.(16) • A single tablet of 100 mg oral tramadol is equivalent to 1000 mg acetaminophen for postoperative pain.(17) • Sustained release morphine was shown to be more effective in severe cancer pain. (8) In Combination
• May be safely combined with NSAIDS. (8) Tramadol has no effect on prostaglandin synthesis and hence no ability to induce GI bleeding or reduced platelet activity.(13) • Does not cause a withdrawal reaction when given to patients receiving morphine or methadone, yet similarly it does not prevent a withdrawal when substituted for potent opioids.(16)
Metabolism and Excretion and Absorption
• Mainly excreted by the kidneys (90%). (4, 8, 16) • Following multiple oral administration of tramadol 100 mg four times daily, Cmax is 16% higher and AUC 36% higher than after a single 100 mg dose, indicating that oral bioavailability increases to approximately 90-100% on multiple administration, possibly due to saturated first-pass hepatic administration. 
INCIDENT PAIN GENERAL PRINCIPLES SUFENTANIL GUIDELINES
• Incident pain can be defined as a new or transiently worsening pain as a result of an action or activity.
• Examples of clinical situations:
• planned turns, transfers or ambulation
• bathing
• changing clothes
• dressing changes or debridement
• disimpaction
• The management of incident pain can be difficult due to its rapid onset, intensity and transient nature.
• Oral analgesics often do not have a rapid enough onset to be effective
• Morphine or Hydromorphone oral solution would be an appropriate first choice in these patients, given 1 hour pre-incident. If not successful, try SC for rapid effect (15-20 minutes) and ensure all other adjuvants have been tried.
• In situations with severe incident pain and above not effective, Sufentanil can be considered
Sufentanil
• Sufentanil is a very potent synthetic opioid agonist that is rapidly absorbed sublingually and has a very short half-life.
• Sufentanil should NOT be used in opioid naïve patients • If Sufentanil is initiated in the home, initial doses should be given under a monitored situation, i.e. RN in the home.
• Sufentanil is approximately 10x more potent than fentanyl (Sublimaze R ) so proper labeling is crucial to prevent any confusion between these agents, especially in hospital.
• Sufentanil is available in 50mcg/ mL amps (1 mL).
• The onset of analgesic action may be as short as 3-5 minutes but wait 10-15 min for full effect -can last for 40 minutes.
• Each dose should be administered under the tongue approximately 10 minutes prior to the activity. The patient should be instructed not to swallow for up to 2 minutes.
• If the initial dose appears to be insufficient, the same dose may be repeated up to 2 additional times every 10-15 minutes -see table below.
